BSX: Clinical Pipeline And Capital Deployment Will Support Rebased Expectations

Boston Scientific's updated analyst price target has shifted lower by about $5.80 to $79.40, as analysts factor in slower growth expectations for the Watchman franchise and slightly softer forecasts for revenue growth, profit margins, and future P/E.

Analyst Commentary

Recent Street research around Boston Scientific reflects a mix of optimism and caution, with most firms trimming price targets to align with updated expectations for the Watchman franchise, organic sales growth, and sector-wide medtech valuations.

Bullish Takeaways

Bullish analysts who cut targets into the US$70 to US$89 range still keep positive ratings. This signals that, even with lower Watchman and organic growth assumptions, they see room for value if the company executes on its broader portfolio and guidance.
Some research points to company commentary that reiterates full year guidance while resetting Watchman expectations. Bullish analysts view this as management getting estimates closer to current execution trends rather than signaling a broad breakdown in the business.
Several positive ratings are anchored to the view that the recent reset and target reductions already factor in slower Watchman growth and softer margins. As a result, current valuation frameworks may already reflect a more conservative growth path.
One bullish research note argues that the Watchman reset is now largely incorporated into the stock. In that view, this could support renewed investor interest if operational delivery stays in line with updated forecasts.

Bearish Takeaways

Bearish analysts highlight the sequentially flat Watchman revenue outlook for Q2 and Q3 and the move to the low end of organic sales guidance as signs that growth execution is facing real pressure. They see this as a risk for current valuation multiples.
Several downgrades and target cuts into the US$50s and low US$60s point to concerns that reduced Watchman guidance, softer electrophysiology expectations, and trimmed long term organic growth estimates could cap upside relative to prior P/E assumptions.
Some research explicitly flags worries about ongoing estimate reductions, including the risk of repeated small cuts to revenue and EPS forecasts. In their view, this could weigh on investor confidence in the growth story.
A few firms reference a broader reset in medtech valuations, with macro factors and slower product cycles cited as additional headwinds that could limit how much investors are willing to pay for Boston Scientific even if execution stabilizes.

What's in the News

Boston Scientific launched a US$2b accelerated share repurchase as part of a previously authorized US$5b buyback plan and expects final settlement by June 30, 2026. The program is anticipated to add about US$0.02 to adjusted EPS in 2026 and reduce share count (source: company announcement, May 18, 2023).
The company agreed to invest US$1.5b for roughly a 34% equity stake in MiRus LLC, with an option to fully acquire the SIEGEL TAVR system business for up to an additional US$3b tied to clinical and regulatory milestones. This is expected to expand its position in structural heart technology (source: company announcement, May 18, 2023).
Boston Scientific reported Q1 2026 revenue growth of 11.6% year over year and adjusted EPS of US$0.80. The company lowered full year 2026 revenue growth guidance to about 7% to 8.5% and trimmed EPS guidance as Watchman, U.S. electrophysiology and urology segments face pressure (source: earnings coverage, May 18, 2026).
Penumbra shareholders approved a proposed US$14.5b merger in which Penumbra will become a wholly owned subsidiary of Boston Scientific. This follows recent acquisitions of Valencia Technologies and Nalu Medical to expand the urology and pain portfolios (source: merger coverage, April 1, 2026).
Positive pivotal FRACTURE trial data for the SEISMIQ 4CE Coronary IVL Catheter met primary safety and effectiveness endpoints. Boston Scientific plans to seek FDA approval with a targeted U.S. launch in the first half of 2027 for treating severely calcified coronary artery disease (source: clinical trial update, May 19, 2026).

Valuation Changes

Fair Value: updated to $79.40, down from $85.19, reflecting a modest reset in the central valuation estimate.
Discount Rate: adjusted slightly higher to 7.85% from 7.82%, signaling a small uptick in the required return used in models.
Revenue Growth: trimmed to 8.06% from 8.50%, indicating more conservative assumptions for future revenue expansion.
Net Profit Margin: revised marginally lower to 18.95% from 19.17%, pointing to a slightly softer long term earnings profile on each dollar of sales.
Future P/E: reduced to 30.31x from 31.88x, suggesting a lower multiple investors may be willing to pay for Boston Scientific's earnings in forward estimates.

18 views

Key Takeaways

Innovation in advanced therapies and strategic acquisitions expand market reach and support margin growth through differentiated, high-value offerings.
Global expansion and efficiency initiatives enhance revenue diversification, improve operational margins, and drive long-term sustainable growth.
Persistent cost pressures, competitive threats, regulatory risks, and integration challenges may limit Boston Scientific's revenue growth, pricing power, and margin resilience moving forward.

Catalysts

About Boston Scientific

Develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide.What are the underlying business or industry changes driving this perspective?

Accelerated adoption of advanced therapies like FARAPULSE (pulsed field ablation) and WATCHMAN-backed by expanded clinical indications, strong safety/efficacy data, and increased physician uptake, particularly in major global markets-positions Boston Scientific for continued above-market procedure growth, benefiting revenue and gross margins.
Broadening global access through double-digit growth in emerging markets, especially Asia Pacific (notably in China and Japan), supports long-term international revenue diversification and offsets potential slowdowns in developed regions, driving total top-line expansion.
Ongoing expansion into ambulatory surgery center (ASC) settings-with regulatory changes likely to facilitate increased procedure volumes-should further boost procedure capacity for minimally invasive therapies, supporting higher recurring revenue and improving capacity constraints.
Investment in proprietary, high-margin technologies (e.g., next-gen mapping, advanced diagnostic tools, differentiated urology/neuromodulation pipelines) combined with successful integration of recent acquisitions (Axonics, SoniVie, Intera, Silk Road) expands Boston Scientific's addressable market and is likely to drive margin expansion as product mix improves.
Enhanced scale and operational efficiency through supply chain initiatives, digitalization, and manufacturing automation-alongside robust cash flow-positions Boston Scientific to expand operating margins and generate sustainable earnings growth over the long term.

Boston Scientific Earnings and Revenue Growth

Boston Scientific Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Boston Scientific's revenue will grow by 8.1% annually over the next 3 years.
Analysts assume that profit margins will increase from 17.3% today to 19.0% in 3 years time.
Analysts expect earnings to reach $4.9 billion (and earnings per share of $3.37) by about June 2029, up from $3.6 billion today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $5.6 billion in earnings, and the most bearish expecting $4.2 billion.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 30.3x on those 2029 earnings, up from 20.1x today. This future PE is greater than the current PE for the US Medical Equipment industry at 24.2x.
Analysts expect the number of shares outstanding to grow by 0.31% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.85%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Risks to Boston Scientific's gross margin and net earnings persist due to ongoing cost headwinds from tariffs (with an expected $100 million impact in the second half of 2025) and the discontinuation of the ACURATE valve, which also signals vulnerability to product lifecycle challenges and regulatory pressures.
Heightened competition from low-cost device manufacturers, especially in endoscopy and urology across Asia and Europe, as well as in MedSurg, risks eroding pricing power and market share, which could suppress future revenue expansion and margin resilience.
Heavy reliance on continual product innovation and acquisition integration (e.g., Axonics, SoniVie, Intera Medical, Silk Road) introduces execution and integration risks; a failure to realize anticipated synergies or operational efficiencies may lead to margin compression and dilute overall earnings growth.
Proposed and actual decreases in U.S. reimbursement rates (such as the 16% proposed cut in physician fee for LAA closure and pending evaluations on ASC code changes) introduce regulatory and payer risk, potentially impacting both volume (through slower adoption) and profit margins.
Secular shifts such as increased adoption of procedures in ambulatory surgery centers (ASCs), price sensitivity in emerging markets, and accelerating healthcare consolidation may shift bargaining power to providers, thus restricting revenue growth opportunities and putting additional pressure on long-term margins and earnings.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $79.4 for Boston Scientific based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $106.0, and the most bearish reporting a price target of just $55.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $26.0 billion, earnings will come to $4.9 billion, and it would be trading on a PE ratio of 30.3x, assuming you use a discount rate of 7.9%.
Given the current share price of $48.31, the analyst price target of $79.4 is 39.2% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Boston Scientific?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Future Growth Plans And Acquisitions Will Drive Broader Market Expansion